# **G9a METHYLTRANSFERASE**

# FROM TRANSGENERATIONAL EPIGENETIC INHERITANCE TO THE DISCOVERY OF NEW G9a INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE.

FACULTY OF PHARMACY AND FOOD SCIENCES

UNIVERSITAT DE BARCELONA

AINA BELLVER SANCHIS

JUNE 9<sup>th</sup>, 2021



Neurociències AT de BARCELONA





### **ALZHEIMER'S DISEASE**



### **ALZHEIMER'S DISEASE**



### The aetiology of Alzheimer's disease is multifactorial.

Drug	Donepezil	Rivastigmine	Galantamine	Memantine	Aducanumab
	(1996)	(2000)	(2001)	(2003)	(2021)
Primary mechanism	AchE inh	AchE inh	AchE inh	NMDA antagonist	Monoclonal antibody



## **EPIGENETICS IN ALZHEIMER'S DISEASE**



### Epigenetic Alterations in Alzheimer's Disease

Jose V. Sanchez-Mut and Johannes Gräff\*

Epigenetic mechanisms in Alzheimer's disease: Implications for pathogenesis and therapy

Jun Wang<sup>a</sup>, Jin-Tai Yu<sup>a,b,c,\*\*</sup>, Meng-Shan Tan<sup>b</sup>, Teng Jiang<sup>c</sup>, Lan Tan<sup>a,b,c,\*</sup>

#### Role of Genes and Environments for Explaining Alzheimer Disease

Margaret Gatz, PhD; Chandra A. Reynolds, PhD; Laura Fratiglioni, MD, PhD; Boo Johansson, PhD; James A. Mortimer, PhD; Stig Berg, PhD; Amy Fiske, PhD; Nancy L. Pedersen, PhD



## **EPIGENETIC MECHANISMS**



### **EPIGENETIC MECHANISMS**



# **G9a METHYLTRANSFERASE**



Protein Data Bank PDB: 208J

H3K9me and H3K9me2 are repressive marks.

Lysine methyltransferase.

Its inhibition restores the neuropathological hallmarks of AD.

#### 2019

### Inhibition of EHMT1/2 rescues synaptic and cognitive functions for Alzheimer's disease

Yan Zheng,<sup>1,2,\*</sup> Aiyi Liu,<sup>1,3,\*</sup> Zi-Jun Wang,<sup>1,4,\*</sup> Qing Cao,<sup>1</sup> Wei Wang,<sup>1</sup> Lin Lin,<sup>1</sup> Kaijie Ma,<sup>1,4</sup> Freddy Zhang,<sup>1</sup> Jing Wei,<sup>1,4</sup> Emmanuel Matas,<sup>1</sup> Jia Cheng,<sup>1</sup> Guo-Jun Chen,<sup>3</sup> Xiaomin Wang<sup>2</sup> and Zhen Yan<sup>1,4</sup>

#### 2019

Epigenetics and memory: Emerging role of histone lysine methyltransferase G9a/GLP complex as bidirectional regulator of synaptic plasticity

Karen Ka Lam Pang<sup>a,b</sup>, Mahima Sharma<sup>a,b,c</sup>, Sreedharan Sajikumar<sup>a,b,\*</sup>

Epigenetic regulation by G9a/GLP complex ameliorates amyloidbeta 1-42 induced deficits in long-term plasticity and synaptic tagging/capture in hippocampal pyramidal neurons

Mahima Sharma,<sup>1,2</sup> Tobias Dierkes<sup>1,3,4</sup> and Sreedharan Sajikumar<sup>1,2</sup> Pharmacological inhibition of G9a/GLP restores cognition and reduces oxidative stress, neuroinflammation and β-Amyloid plaques in an early-onset Alzheimer's disease mouse model

Christian Griñán-Ferré<sup>1</sup>, Laura Marsal-García<sup>1</sup>, Aina Bellver-Sanchis<sup>1</sup>, Shukkoor Muhammed Kondengaden<sup>2</sup>, Ravi Chakra Turga<sup>3</sup>, Santiago Vázquez<sup>4</sup>, Mercè Pallàs<sup>1</sup>

2019 – First study in vivo in AD transgenic mice model

www.aging-us.com

### **EPIGENETICS IN 5XFAD**



Pharmacological inhibition of G9a/GLP restores cognition and reduces oxidative stress, neuroinflammation and  $\beta$ -Amyloid plaques in an early-onset Alzheimer's disease mouse model

Christian Griñán-Ferré<sup>1</sup>, Laura Marsal-García<sup>1</sup>, Aina Bellver-Sanchis<sup>1</sup>, Shukkoor Muhammed Kondengaden<sup>2</sup>, Ravi Chakra Turga<sup>3</sup>, Santiago Vázquez<sup>4</sup>, Mercè Pallàs<sup>1</sup>





#### Oxidative stress



# Wt Control 5XFAD Control 5XFAD UNC0642 (5mg/Kg)

### Better cognitive performance



**Epigenetic modifications** 



Values represented are mean  $\pm$  Standard error of the mean (SEM); (n = 24 (SAMP8 Control = 12, SAMP8 UNC0642 (5mg/Kg) n = 12)). \*p<0.05; \*\*p<0.001; \*\*\*\*p<0.001; \*\*\*\*p<0.001.

www.aging-us.com

Pharmacological inhibition of G9a/GLP restores cognition and reduces

oxidative stress, neuroinflammation and β-Amyloid plaques in an

Christian Griñán-Ferré<sup>1</sup>, Laura Marsal-García<sup>1</sup>, Aina Bellver-Sanchis<sup>1</sup>, Shukkoor Muhammed

AGING 2019, Vol. 11, Advance

**Research Paper** 

### **EPIGENETICS IN 5XFAD**



early-onset Alzheimer's disease mouse model

Kondengaden<sup>2</sup>, Ravi Chakra Turga<sup>3</sup>, Santiago Vázquez<sup>4</sup>, Mercè Pallàs<sup>1</sup>

Inflammation

Better cognitive performance



### Amyloid plaques



# **MISSING HERITABILITY**



Most disease heritability remains unaccounted



### Epigenetic differences arise during the lifetime of monozygotic twins

Mario F. Fraga\*, Esteban Ballestar\*, Maria F. Paz\*, Santiago Ropero\*, Fernando Setien\*, Maria L. Ballestar<sup>†</sup>, Damia Heine-Suñer<sup>†</sup>, Juan C. Cigudosa<sup>5</sup>, Miguel Urioste<sup>1</sup>, Javier Benitez<sup>1</sup>, Manuel Boix-Chornet<sup>†</sup>, Abel Sanchez-Aguilera<sup>†</sup>, Charlotte Ling<sup>1</sup>, Emma Carlsson<sup>1</sup>, Pernille Poulsen\*\*, Allan Vaag\*\*, Zarko Stephan<sup>††</sup>, Tim D. Spector<sup>††</sup>, Yue-Zhong Wu<sup>11</sup>, Christoph Plass<sup>11</sup>, and Manel Esteller<sup>\*55</sup>



MDPI

Review

The Contribution of Epigenetic Inheritance Processes on Age-Related Cognitive Decline and Alzheimer's Disease

Aina Bellver-Sanchis<sup>1</sup>, Mercè Pallàs<sup>1</sup> and Christian Griñán-Ferré<sup>1,\*</sup>

Does **set-25** play an important role in **epigenetic inheritance** in cognitive impairment after environmental harmful insults?

### EXPERIMENTAL PARADIGM

Imprinting: a phase-specific long-term memory





## CONCLUSIONS

- The potential reversibility of epigenetics allows **predicting future disease risk** and **validating new therapeutic targets**, as epigenetic intervention can modify the hippocampal transcriptome, potentially reversing age-related cognitive dysfunction. **Epigenetics**, therefore, is of **considerable translational importance** in the field of **neuroprotection**.
- UNC0642 prevented A**β** plaques accumulation, increased **synaptic plasticity** and neuronal markers that are characteristically loss in AD. Moreover, UNC0642 was able to reduce **OS** and **neuroinflammation**.





Dra Mercè Pallàs Dr Christian Griñán Ferré Dra Anna M. Canudas

Gràcies NK YOU

Foteini Vasilopoulou Vanessa Izquierdo Júlia Companys Júlia Jané

### TAKE HOME MESSAGE

Our work reports a new finding that pharmacological inhibition of **G9a** might be a promising target for AD therapy, promoting neuroprotection through reduction of its repressive chromatin mark



Institut de Neurociències UNIVERSITAT DE BARCELONA



